Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Corden Pharma Boulder, Inc.
483
•Corden Pharma Boulder, Inc.•May 11, 2012

Corden Pharma Boulder, Inc. – FDA 483, May 11, 2012

Record Details

The FDA inspection revealed significant deficiencies at the facility, many of which were repeat observations from a June 21, 2011 audit. The firm commercially distributed 18 lots of Carboplatin without process validation, and the pH method for Carboplatin finished product and stability testing was unreliable between 2006 and 2011, impacting all distributed lots. Carboplatin lot# (b)(4) failed stability pH testing but was commercially distributed.

The firm failed to submit Field Alert Reports within three working days for numerous out-of-specification (OOS) stability API samples supporting marketed drug products, including Carboplatin, Pentostatin, Sodium Nitroprusside, and Pamidronic Acid. The issue elevation process did not account for unconfirmed stability failures.

Laboratory controls were inadequate; a Pentostatin stability sample OOS for assay was retested, and an outlier result was discarded without proper documentation or SOPs for outlier identification. Cleaning validation for equipment used interchangeably between multiple active pharmaceutical ingredients (Carboplatin, Paclitaxel, Pamidronic Acid, Pentostatin, Sodium Nitroprusside, Tromethamine, Irinotecan, Oxaliplatin) was incomplete. A Paclitaxel API cleaning validation attempt failed due to a manufacturing deviation.

The quality control unit lacked responsibility for approving laboratory procedures; an instrument SOP was changed via email without QC approval, impacting GMP assays for Carboplatin and Oxali

Company
Corden Pharma Boulder, Inc.
Inspection date
May 11, 2012
Product type
Drugs
Office
Denver District Office
People
  • Kimberley A. Hoefen (Consumer Safety Officer )
  • Erika V. Butler (Compliance Officer / Investigator)
View Company Profile

ID · c3aeb11c-d9c2-4076-8a96-ad4ef508229e

Violation Codes5
21 U.S.C. 324(a)(4)21 CFR 21021 CFR 211FD&C Act 801(a)(3)21 CFR 331(c)

Full citation text and observation details available on the Dashboard.

Other documents for Corden Pharma Boulder, Inc.
  • 483 - 2011-06-21June 21, 2011

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Corden Pharma Boulder, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.